Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LEXINGTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free...
-
REDWOOD CITY, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
-
MORRIS PLAINS, N.J., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a...
-
SANTA CLARITA, CA--(Marketwired - Jan 5, 2015) - U.S. ENERGY INITIATIVES CORPORATION INC (OTC PINK: USEI) is pleased to announce today that the FINRA has approved a stock 20% restricted stock...
-
MOUNTAIN VIEW, CA--(Marketwired - Jan 5, 2015) - Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced a research and development partnership with...
-
RUTHERFORD, N.J., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"), an emerging leader in DNA-based cancer diagnostics, announced today that its...
-
PRINCETON, N.J., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it submitted an...
-
SAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
-
CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the Company's newly implemented strategy for accelerated growth. The...
-
Upcoming milestones include: Top-line data from ongoing first Phase III study with RHB-105 for H. pylori infection expected Q2/2015 Top-line data from ongoing Phase III study with...